Abstract
Background/aimsInvestigation of gastro-oesophageal reflux disease is usually performed off proton pump inhibitors (PPIs). This can exacerbate symptoms, potentially impacting investigation accuracy if patients circumvent the preinvestigation instructions. There are no standard recommendations on how to manage PPI withdrawal. We aimed to assess the impact of structured alginate use on symptom burden.MethodsParticipants were already established on ≥4 weeks of PPI therapy and being referred for manometry and 24-hour pH/impedance testing. Preinvestigation instructions involved stopping PPIs and H2 receptor antagonists for 1 week, but antacids and alginates were allowed until the night before. Participants were randomised to follow these standard instructions (control group), or the same instructions with the provision of Gaviscon Advance to be taken four times daily (treatment group). The primary outcome assessed change in Gastro-Oesophageal Reflux Disease Health-Related Quality of Life Score.Key resultsData for 48 patients were available for primary outcome assessment. While patients in the control group had a significant increase in symptoms (median difference 6.5, 95% CI (1 to 7), p=0.04), no change occurred in the treatment arm (median difference -1.5, 95% CI (-2, 3.5), p=0.54). There were no serious adverse events.ConclusionsStructured alginate use prevents symptom exacerbation during preinvestigation PPI wash-out. These findings are limited to the 1-week wash-out period but can benefit thousands of patients undergoing investigation for gastro-oesophageal reflux each year. Further research is required to assess this effect in other settings, such as sustained PPI deprescription. The trial was funded by Reckitt Benckiser.Trial registration numberEudraCT registration 2019-004561-41
Funder
Reckitt Benckiser Pharmaceuticals
Reference35 articles.
1. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review
2. Economic Evaluations of Gastroesophageal Reflux Disease Medical Management
3. NHS Digital . Prescription cost analysis, 2018. Available: https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis
4. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management . National Institute for health and care excellence: clinical guidelines. London, 2019.
5. Short-Term Treatment with Proton-Pump Inhibitors as a Test for Gastroesophageal Reflux Disease
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献